Document is current
Any future updates will be listed below
-
Authors
Sakellakis, Minas J.
Hahn, Andrew W. https://orcid.org/0000-0002-4153-205X
Ramachandran, Sumankalai
Zhang, Miao
Hoang, Anh
Song, Jian H.
Liu, Jingjing
Wang, Feng
Basu, Hirak S.
Sheperd, Peter
Wang, Xuemei
Frigo, Daniel E. https://orcid.org/0000-0002-0713-471X
Lin, Sue-Hwa
Panaretakis, Theocharis
Zhang, Jianhua
Navone, Nora https://orcid.org/0000-0001-8645-6890
Troncoso, Patricia
Logothetis, Christopher J. https://orcid.org/0000-0002-6365-1711
Titus, Mark A.
-
Funding
Funding for this research was provided by:
David H. Koch Center for Applied Research of Genitourinary Cancers
- License Information
-
More Information
Article History
Received: 11 March 2022
Revised: 26 July 2022
Accepted: 24 August 2022
First Online: 13 September 2022
Competing interests
: DEF has received research funding from GTx, Inc and has a familial relationship with Hummingbird Bioscience, Maia Biotechnology, Alms Therapeutics, Hinova Pharmaceuticals, and Barricade Therapeutics. CJL reports commercial research grants from Janssen, ORIC Pharmaceuticals, Novartis, Aragon Pharmaceuticals, and honoraria from Merck, Sharp, and Dohme, Bayer, and Amgen. The other authors report no potential conflicts of interest.
: Informed consent was obtained from each patient for the studies described above and subsequent publication.
: This study was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board and the IACUC committee.
